Summary
This 2023 Nature Genetics paper presents a comprehensive genomic atlas integrating large-scale GWAS data to map genetic determinants of plasma metabolites and prioritise those mechanistically linked to human diseases. By combining metabolomic profiling with genomic analysis across multiple cohorts, the authors identified metabolites as potential biomarkers or therapeutic targets in disease pathways. The work contributes to understanding the genetic architecture of human metabolism and its relevance to chronic disease risk.
UK applicability
The genomic findings may be applicable to UK clinical practice and personalised medicine strategies, particularly in identifying metabolic biomarkers for disease screening and prevention. However, metabolite-disease associations may vary across UK populations depending on genetic ancestry, dietary patterns, and environmental factors; further UK-specific validation cohorts would strengthen clinical applicability.
Key measures
Plasma metabolite concentrations; genetic variants (SNPs) associated with metabolite abundance; disease-metabolite associations; heritability estimates for metabolite traits
Outcomes reported
The study conducted a large-scale genome-wide association study (GWAS) to identify genetic variants affecting plasma metabolite levels and prioritise metabolites implicated in human disease pathways. It generated a genomic atlas linking genetic variation to metabolic profiles relevant to disease aetiology.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.